Integra LifeSciences (NASDAQ:IART) Trading Down 3.3% - Here's Why

Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) shares were down 3.3% during mid-day trading on Wednesday . The stock traded as low as $13.64 and last traded at $13.51. Approximately 268,272 shares traded hands during trading, a decline of 74% from the average daily volume of 1,037,474 shares. The stock had previously closed at $13.98.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on IART shares. Truist Financial reduced their price target on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Wells Fargo & Company reduced their price target on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. JMP Securities reduced their price target on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. JPMorgan Chase & Co. reduced their price target on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Finally, Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Four investment analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $18.63.

Integra LifeSciences Trading Down 4.2%

The company has a market cap of $944.98 million, a PE ratio of -135.10, a PEG ratio of 0.73 and a beta of 1.16. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The stock has a 50 day moving average price of $14.50 and a 200 day moving average price of $20.21.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its earnings results on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). The firm had revenue of $382.65 million during the quarter, compared to analysts' expectations of $381.17 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company's revenue for the quarter was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.55 EPS. Sell-side analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Quadrant Capital Group LLC raised its stake in Integra LifeSciences by 5,960.9% during the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after buying an additional 1,371 shares during the last quarter. Sterling Capital Management LLC raised its stake in Integra LifeSciences by 821.7% during the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after buying an additional 1,931 shares during the last quarter. Covestor Ltd raised its stake in Integra LifeSciences by 61.8% during the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock valued at $123,000 after buying an additional 2,071 shares during the last quarter. CWM LLC raised its stake in shares of Integra LifeSciences by 413.8% in the first quarter. CWM LLC now owns 6,664 shares of the life sciences company's stock worth $147,000 after purchasing an additional 5,367 shares during the last quarter. Finally, Empowered Funds LLC purchased a new position in shares of Integra LifeSciences in the fourth quarter worth $180,000. Hedge funds and other institutional investors own 84.78% of the company's stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.